FTX003059

FTX003059 is a topical small molecule therapeutic being developed by Fountain Therapeutics (also known as Green Fountain) for the treatment of various skin atrophy conditions. Identified through Fountain's AI-driven platform, which focuses on reversing cellular aging by restoring healthy cell function, FTX003059 is being evaluated both as a monotherapy and as part of a topical combination product (with FTX002600). The drug is intended to treat age-associated skin atrophy, glucocorticoid-induced skin atrophy, scleroderma, and weight loss-associated skin atrophy (colloquially referred to as "Wegovy Face"). It is also positioned for use in medical aesthetics as a potential alternative to dermal fillers or neurotoxins. The program is currently in the preclinical and IND-enabling stages of development.